

Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2015

(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the *Autorité des Marchés Financiers*)

Charenton-le-Pont, France (March 6, 2015 - 6:00 p.m.) – As of February 28, 2015, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

February 28, 2015

| | |
|---|-------------|
| Shares outstanding | 216,022,340 |
| Exercisable voting rights | 228,594,685 |
| Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 232,554,606 |

(*) Shares held by the Company.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To fulfill it, Essilor allocates more than €150 million to research and innovation every year, in a commitment to continuously bringing new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Definity®, Xperio®, Optifog™, Foster Grant®, Bolon® and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of nearly €5.7 billion in 2014 and employs 58,000 people. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as several research and development centers around the world. For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16